Amlodipine
- Generic Name
- Amlodipine
- Brand Names
- Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25ClN2O5
- CAS Number
- 88150-42-9
- Unique Ingredient Identifier
- 1J444QC288
- Background
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnorma...
- Indication
Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :
• Hypertension
• Coronary artery disease
• Chronic stable angina
• Vasospastic angina (Prinzmetal’s or Variant angina)
...
- Associated Conditions
- Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina
- Associated Therapies
- -
A Study to Evaluate the Effects of Manidipine Versus Amlodipine and the Combination of Manidipine Plus Delapril Versus Amlodipine Plus Delapril on Intraglomerular Pressure in Hypertensive Patients
- Conditions
- Interventions
- First Posted Date
- 2008-03-04
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 100
- Registration Number
- NCT00627952
- Locations
- 🇩🇪
Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nurnberg, Erlangen, Bavaria, Germany
Bioequivalency Study of Amlodipine Tablets Under Fasting Conditions
- Conditions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 40
- Registration Number
- NCT00602017
- Locations
- 🇺🇸
Gateway Medical Research, Inc., Saint Charles, Missouri, United States
Bioequivalency Study of Amlodipine Tablets Under Fed Conditions
- Conditions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 40
- Registration Number
- NCT00601302
- Locations
- 🇺🇸
Gateway Medical Research, Inc., Saint Charles, Missouri, United States
Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 566
- Registration Number
- NCT00591266
Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension
- Conditions
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1098
- Registration Number
- NCT00558428
- Locations
- 🇳🇱
1235.5.31004 Boehringer Ingelheim Investigational Site, Hoogwoud, Netherlands
🇳🇱1235.5.31003 Boehringer Ingelheim Investigational Site, Musselkanaal, Netherlands
🇳🇱1235.5.31005 Boehringer Ingelheim Investigational Site, Roelofarendsveen, Netherlands
Filtered Trial for Amlodipine Non-responder
- Conditions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 531
- Registration Number
- NCT00558064
- Locations
- 🇯🇵
1235.13.009 Boehringer Ingelheim Investigational Site, Kiyose, Tokyo, Japan
🇯🇵1235.13.002 Boehringer Ingelheim Investigational Site, Sendai, Miyagi, Japan
🇯🇵1235.13.038 Boehringer Ingelheim Investigational Site, Kitaazumi-gun, Nagano, Japan
Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension
- Conditions
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 947
- Registration Number
- NCT00553267
- Locations
- 🇧🇬
1235.6.35904 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria
🇮🇪1235.6.35304 Wilmer Road, Birr, Ireland
🇧🇬1235.6.35902 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2011-05-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 178
- Registration Number
- NCT00542269
- Locations
- 🇬🇧
Addenbrookes Hospital, Cambridge, United Kingdom
A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Third Military Medical University
- Target Recruit Count
- 360
- Registration Number
- NCT00538486
- Locations
- 🇨🇳
The third hospital affiliated to the Third Military Medical University, Chongqing, China
Nephropathy In Type 2 Diabetes and Cardio-renal Events
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 850
- Registration Number
- NCT00535925
- Locations
- 🇮🇹
Department of Advanced Medical and Surgical Sciences, Università della Campania "Luigi Vanvitelli", Naples, Italy, Naples, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.